Dianthus Therapeutics, Inc. - Common Stock DNTH 深 滬
等待開盤 09-11 09:30:00 美东时间
37.90
+2.330
+6.55%
華盛通- 最 高38.25
- 今 開33.89
- 成交量 286.10万股
- 最 低 33.23
- 昨 收 35.57
- 總市值 12.20亿
- 52周最高 38.25
- 市盈率 靜 --
- 換手率 0.01%
- 52周最低 13.365
- 委 比 -66.67%
- 總股本 3218.83万
- 歷史最高 336.00
- 量 比 1.52
- 振 幅 14.11%
- 歷史最低 5.136
- 每 手 1
- 風險率 3.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅577.08%！Veritone获D. Boral Capital升目标价至26美元，维持"买入"评级
今日重点评级关注：D. Boral Capital：维持Veritone"买入"评级，目标价从6美元升至26美元；Guggenheim：维持Dianthus Therapeutics"买入"评级，目标价从92美元升至100美元
09-10 18:01
Dianthus Therapeutics prices upsized $251M securities offering
Dianthus Therapeutics (NASDAQ:DNTH) has priced its recently announced and upsized public offering, raising approximately $251 million in gross proceeds, by selling 6.49 million shares of common stock ...
09-10 15:10
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering
Dianthus Therapeutics raised approximately $251 million through an upsized public offering of 6,487,879 shares of common stock at $33.00 per share, with an additional option for underwriters to purchase up to 1,140,000 more shares. The company aims to use the net proceeds to advance its preclinical and clinical development, as well as for general corporate purposes. The offering is set to close on September 11, 2025, subject to customary closing ...
09-10 02:35
Analyst Expectations For Dianthus Therapeutics's Future
In the preceding three months, 4 analysts have released ratings for Dianthus Th...
09-09 22:01
Dianthus Therapeutics launches $150M underwritten public offering
Dianthus Therapeutics (NASDAQ:DNTH) has commenced an underwritten public offering of $150M of its shares of its common stock, pre-funded warrants to purchase shares of its common stock. Dianthus inten...
09-09 04:07
Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile
Dianthus Therapeutics announced positive results from the Phase 2 MaGic trial of claseprubart (DNTH103) for generalized Myasthenia Gravis (gMG). Both 300mg and 600mg Q2W doses achieved statistically significant and clinically meaningful improvements in MG-ADL and QMG scores at Week 13, with rapid onset of action at Week 1. The 300mg dose also showed significant improvements across MSE, MGC, and MG-QoL-15r scores. Claseprubart demonstrated a favor...
09-08 11:00
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis
Dianthus Therapeutics announced a conference call and webcast to discuss Phase 2 MaGic trial results for claseprubart (DNTH103) in generalized Myasthenia Gravis on September 8, 2025, at 8:00 a.m. EDT. Investors can access the call via registration or through a live webcast on the company’s website, www.dianthustx.com. The company specializes in developing next-generation antibody complement therapeutics for severe autoimmune diseases.
09-07 22:25
Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $42
Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $34 to $42.
08-21 21:32
美股牛股 | 区域银行DSBX获并购，股价单日飙涨54%！AI国防概念VisionWave大涨18%
美股牛股 | 区域银行DSBX获全资并购，股价单日飙涨54%！AI国防概念VisionWave大涨18.4%，推出实时嵌入式AI引擎>>
08-20 18:57
William Blair Initiates Coverage On Dianthus Therapeutics with Outperform Rating
William Blair analyst Myles Minter initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform rating.
07-03 03:01
